Roivant Sciences
(NASDAQ) ROIV
Roivant Sciences Financials at a Glance
Market Cap
$26.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$8.26M
Net Income (TTM)
-$299.77M
EPS (TTM)
-$0.50
P/E Ratio
-72.10
Dividend
$0.00
Beta (Volatility)
1.04 (Average)
Dividend
$0.00
Beta (Volatility)
1.04 (Average)
Price
$36.15
Volume
4,267,939.458
Open
$36.15
Price
$36.15
Volume
4,267,939.458
Open
$36.15
Previous Close
$36.09
Daily Range
$35.41 - $36.63
52-Week Range
$10.90 - $36.63
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
1.04 (Average)
Price
$36.15
Volume
4,267,939.458
Open
$36.15
Previous Close
$36.09
Daily Range
$35.41 - $36.63
52-Week Range
$10.90 - $36.63
Estimated Earnings Date
Aug 10, 2026
ROIV News
ROIV: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Roivant Sciences
Industry
Biotechnology
Sector
Health CareEmployees
721
CEO
Matthew Gline
Website
www.roivant.comHeadquarters
London, GL SW1Y 4LB, GB
ROIV Financials
Key Financial Metrics (TTM)
Gross Margin
84.44%
Operating Margin
-15560.57%
Net Income Margin
-3629.19%
Return on Equity
-6.85%
Return on Capital
-27.73%
Return on Assets
-5.23%
Earnings Yield
-1.39%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$26.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
719.27M
Volume
4.27M
Avg. Volume
5.93M
Financials (TTM)
Gross Profit
$6.98M
Operating Income
-$1.29B
EBITDA
-$261.23M
Operating Cash Flow
-$750.35M
Capital Expenditure
-$8.21M
Free Cash Flow
-$758.56M
Cash & ST Invst.
$4.30B
Total Debt
$107.44M
Roivant Sciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.52M
-66.7%
Gross Profit
$2.20M
-70.1%
Gross Margin
87.30%
N/A
Market Cap
$26.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$36.22M
N/A
Employees
721
N/A
Net Income
$302.99M
+246.7%
EBITDA
$454.74M
+325.5%
Quarterly Fundamentals
Total Cash
$4.30B
-12.1%
Total Debt
$107.44M
+7.3%
Accounts Receivable
$789.84M
N/A
Inventory
$0.00
N/A
Long Term Debt
$96.29M
+6.6%
Short Term Debt
$11.15M
+13.3%
Return on Assets
-5.23%
N/A
Return on Invested Capital
-23.60%
N/A
Free Cash Flow
-$165.08M
+4.8%
Operating Cash Flow
-$163.82M
+5.1%